Recovering scientist turned early stage VC A biotech optimist fighting gravity

Patients: Our Purpose, Our Partners
July 9, 2014

My first experience in this life sciences industry, many years ago, was working as a pharmacist in a small town in the midwest. My most valued memories from that time were the instances when I was able to engage directly

2 Comments

Growing Beyond The Startup Phase: Lessons learned
July 1, 2014

So your biotech startup’s graduated to a Series A financing and your investors believe there’s nothing but champagne and robust clinical data in your future. Some classic analogies are applicable here; you’ve found a way off the island, you’ve defeated

Leave a comment

Soccer, The World Cup, And Biotech
June 30, 2014

Soccer is a fantastic sport – eleven players on a side, a hundred yards of pitch, one ball, and lots of emotion. Watching the World Cup this year has been fun; our children are just now old enough where they

5 Comments

Operating Inside The Atlas Seed Portfolio
June 27, 2014

In early 2013, I enlisted as an entrepreneur-in-residence (EIR) with the Atlas Venture life science investment team as the firm focused on a seed-led investing strategy as a core tenant of Fund IX (here).  I viewed it as a great

1 Comment

Zafgen Supersizes Its Obesity-Focused IPO: An Early Investor’s Reflections
June 25, 2014

Last week we priced the IPO for Zafgen – embarking on a new phase for the company (here).  Upsized at the top of the range, the offering is a testimony to the great team and exciting story at Zafgen. In line

1 Comment

A Tale of Disruptive Science, Irreproducibility, and Unanticipated Consequences
June 13, 2014

I’ve spent a significant amount of my career focused on the use of nucleic acids as therapeutic agents.  The ability of nucleic acids to act through exquisitely selective binding to other nucleic acids, proteins or other biologically active molecules provides

1 Comment

Goldilocks & The Pace Of Biotech Startup Creation
June 11, 2014

How many new biotechs should the industry be starting per year?  It’s a perennially asked question, and obviously not one with an easy and straightforward answer. On the one hand, if you believe only transformational new ideas should get funding,

4 Comments

Biotech’s Virtual Reality
June 4, 2014

Much has been written about the merits and demerits of the virtual biotech model.  In essence, a virtual biotech outsources all non-core activities and rejects the need for in-house laboratories.  Instead, a small internal team manages execution outside the company,

3 Comments

Atlas’ IQ Just Got A Raise: Dave Grayzel
May 21, 2014

Today we’re excited to announce the addition of Dave Grayzel as a Partner on our life sciences team.  Dave has been a key contributor to our strategy since joining Atlas Venture in 2010 to lead our asset-centric, collaborative investing initiative

1 Comment

Talent Acquisition: Pharma Is The Lifeblood Of Biotech
May 19, 2014

Startup Biotechs need bigger drug companies for lots of things, including R&D collaborations, investments, non-dilutive funding, and eventual liquidity via M&A. The health of today’s ecosystem depends on biotech and pharma working together. But one of the most important and

4 Comments

Risk: A User’s Guide For Drug Developers
May 14, 2014

In my last post, I argued that the key to the success – and perhaps even the survival – of the biopharma industry is to excel at risk management. We are in an inherently risky business, where there are thousands of

8 Comments

Leveraging Nature’s Experiments: Mitigating Drug Discovery Risks Through Human Genetics
May 8, 2014

Extreme clinical phenotypes caused by rare genetic variations have been the basis of some of the most exciting drug targets in today’s pharmaceutical pipeline: PCSK9 in cholesterol, sclerostin in bone diseases, Nav1.7 for pain.  The rare gene signatures underlying these

4 Comments